Last reviewed · How we verify
NCT03531216
Topical Rosemary Oil Application in Systemic Sclerosis
NA trial testing Rosemary essential oil in Systemic Sclerosis in 12 participants. Completed in 21 March 2016.
21 March 2016
Quick facts
| Lead sponsor | ARCIM Institute Academic Research in Complementary and Integrative Medicine |
|---|---|
| Phase | NA |
| Status | Completed |
| Study type | INTERVENTIONAL |
| Allocation | non randomized |
| Design | crossover |
| Masking | none |
| Primary purpose | treatment |
| Enrollment | 12 |
| Start date | 2 November 2015 |
| Primary completion | 21 March 2016 |
| Estimated completion | 21 March 2016 |
| Sites | 2 locations across Germany |
Drugs / interventions tested
- Rosemary essential oil
- Placebo
Conditions studied
- Systemic Sclerosis — all drugs for Systemic Sclerosis →
Sponsor
ARCIM Institute Academic Research in Complementary and Integrative Medicine
Who can join
18 and older, any sex, with Systemic Sclerosis. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
The objectives of this prospective crossover, open-label, nonrandomized study are to estimate effect sizes of vasodilatation and sense of warmth after application of topical rosemary essential oil in patients suffering from systemic sclerosis.
Publications & conference data
No peer-reviewed publications indexed yet for this trial. Completed trials usually publish results within 12-18 months.
Verify or expand the search:
- PubMed search for NCT03531216
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other recruiting trials for Systemic Sclerosis
Currently open trials in the same condition.
- NCT07335562 — A Study to Compare the Efficacy and Safety of BMS-986353 (Zolacabtagene- Autoleucel / Zola-cel), CD19-CAR T Cells, Versu · Phase 3 · recruiting
- NCT06947473 — Umbilical Cord Blood CD19-BCMA CART Cell Therapy for SLE-LN, SSc, andpSS PAH. · Phase 1, PHASE2 · recruiting
- NCT07047690 — A Study of Nemolizumab for the Treatment of Adults With Systemic Sclerosis · Phase 2 · recruiting
- NCT07246096 — Exploratory Clinical Study on the Safety and Efficacy of Anti- CD19/BCMA U CAR-T Cell Injection for the Treatment of Rel · EARLY_PHASE1 · recruiting
- NCT07295847 — A Study of AZD0120 in Autoimmune Diseases · Phase 1 · recruiting
Other ARCIM Institute Academic Research in Complementary and Integrative Medicine trials
Trials by the same sponsor.
- NCT05855044 — Efficacy of External Application of Rosemary Oil in Patients With Chemotherapy-Induced Peripheral Neuropathy: a Feasibil · NA · completed
- NCT05547178 — Changes in Everyday Life After a Tai Chi or Eurythmy Intervention in Elderly People at Risk of Falling: a Qualitative Ex · completed
- NCT05236179 — Survey of Inpatients on Integrative Therapy Methods · completed
- NCT04893343 — Antibiotic Use in a Neonatal Intensive Care Unit Practicing Integrative Medicine · completed
- NCT04579497 — Temperature-dependent Changes in Cardiovascular Parameters During Warm Water Footbaths in Healthy Women · NA · completed
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT03531216 (US National Library of Medicine, public domain)
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by ARCIM Institute Academic Research in Complementary and Integrative Medicine
- Last refreshed: 10 January 2019
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT03531216.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing